Four weeks at 0.25 mg is how an Ozempic dosage schedule starts, and that month is the part people misread. Its job is to let the gut adapt. The maintenance doses the trials measured arrive later, at 0.5 mg, 1 mg and 2 mg, and each step waits at least four weeks.
The starting dose is a warm-up. The working doses start at week five. The 0.25 mg month is not a treatment dose in the sense that matters to a patient: the label describes it as the initiation dosage, and the numbers behind it come from a safety table about stomach upset, not from a blood sugar table about results.
Ozempic Dosage – The Ladder the Label Uses
Section 2.2 of the current Ozempic prescribing information sets a fixed order and a hard ceiling. Inject 0.25 mg once weekly for four weeks. After those four weeks, move to 0.5 mg once weekly. If more blood sugar control is needed, step to 1 mg once weekly after at least four weeks on 0.5 mg. If more control still is needed, step to 2 mg once weekly after at least four weeks on 1 mg.
Two milligrams is the maximum recommended dose. The injection goes under the skin in the abdomen, thigh or upper arm, once weekly, on the same day each week, at any time of day, with or without food.
One subgroup runs on a different ladder. For the kidney and cardiovascular risk indications in the same label, the maintenance dose is 1 mg once weekly, reached after at least four weeks on 0.5 mg. That is the label’s own route for reducing the risk of sustained decline in kidney function and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Notice what is missing from the indication list. Ozempic carries no weight-loss indication. It is labeled for blood sugar control, for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and for the kidney outcomes above. The 89.9 kg average baseline weight of the patients in the label’s trials is context, not a promise.
Ozempic Dosage – Why the Climb Is Deliberately Slow
The escalation rule reads like caution. It is arithmetic. In the pooled placebo-controlled trials in the label’s Table 1, gastrointestinal reactions rose with the dose: 15.3% on placebo, 32.7% at 0.5 mg, 36.4% at 1 mg. Nausea ran 6.1% on placebo, 15.8% at 0.5 mg, 20.3% at 1 mg. Vomiting at 1 mg hit 9.2%, against 2.3% on placebo.
Fewer than one in a hundred placebo patients quit over stomach side effects, 0.4%. The dropout rate climbed with the dose, to 3.1% at 0.5 mg and 3.8% at 1 mg. In the separate trial that tested 1 mg against 2 mg, the gastrointestinal reaction rate came in at 34% for the higher dose against 30.8% for the lower one.
Heart rate moves too. Patients on 0.5 mg and 1 mg averaged a rise of 2 to 3 beats per minute, while the placebo group averaged a fall of 0.3 beats per minute.
The slow climb is the studied part of this drug. There is no trial in the label where a patient skipped the ramp and the paperwork still smiled.
A Missed Week – The Five-Day Window
Section 2.1 answers the question that sends people searching at midnight. If a dose is missed, take it as soon as possible within five days after the missed dose. If more than five days have passed, skip it and take the next dose on the regular scheduled day, then resume the normal weekly pattern.
Changing the weekday is allowed, with one condition: at least two days, meaning more than 48 hours, between two doses. Walking the shot from Saturday to Monday eats into that minimum, and the label says so in plain numbers.
The Pill Under the Same Name – 1.5 mg, 4 mg, 9 mg
The Ozempic name now covers a daily tablet as well as the weekly pen, and the two products do not share a dose chart. The tablet label, revised 1 January 2026, runs on days rather than weeks: 1.5 mg once daily for days 1 to 30, then 4 mg once daily for days 31 to 60, then either 4 mg or 9 mg once daily from day 61 onward if more blood sugar control is needed.
The tablet label states the 1.5 mg starting dose is not effective for glycemic control. It is a tolerance step. The dose count for the tablets also comes with a substitution warning written into the label: the tablets are not substitutable on a milligram-to-milligram basis, and the label publishes exact switch paths instead of a conversion rule. Rybelsus 7 mg maps to Ozempic tablets 4 mg. Rybelsus 14 mg maps to Ozempic tablets 9 mg. From the 0.5 mg injection, a person can move to the tablets one week after the last injection.
The tablets carry their own ritual, all of it in section 2.1: swallow one whole, on an empty stomach in the morning, with no more than four ounces of plain water, then wait at least 30 minutes before food, other drinks, or other oral medicines. A 2 mg ceiling on the pen and a 9 mg ceiling on the pill are not the same drug day. That is why the pill is counted in days and the pen in weeks, and why reading one schedule as the other is a mistake with a milligram sign on it.
For the Wegovy side of the family, which is the same molecule under a different indication, the label numbers sit in our breakdown of Wegovy’s side effect rates, and the dosing ceiling there is a different number again.
The Compounded Vial – Where Milligrams Stop Meaning Anything
This is the part of the Ozempic dosage conversation the drug maker’s label cannot answer, because a compounded vial is not that product.
The FDA states the position without decoration: compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they reach a patient. On its page about unapproved GLP-1 drugs, the agency reports receiving multiple adverse event reports, some requiring hospitalization, that may relate to dosing errors with compounded injectable semaglutide. It also reports patients receiving compounded semaglutide or tirzepatide in doses beyond the approved label, which in practice means more product in one shot, doses taken more often, or a faster climb than the label allows.
The FDA counts what it gets. As of 31 May 2026 it had logged 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. It also flags that some compounded semaglutide on the market arrives as salt forms such as semaglutide sodium or semaglutide acetate, which are different active ingredients from the semaglutide in the approved products.
The legal window narrowed as well. On 21 February 2025 the FDA determined the semaglutide injection shortage was resolved, having confirmed with the manufacturer that supply and capacity could meet projected national demand. That determination ended the enforcement discretion compounders had leaned on: for state-licensed pharmacies and physicians under section 503A it ran to 22 April 2025, and for outsourcing facilities under section 503B to 22 May 2025. The FDA states that compounded drugs belong to patients whose medical needs cannot be met by an approved drug.
Here is the practical translation for someone holding a vial and a clinic’s typed chart. The dose numbers in this article come from trials of the approved pens and tablets, with the trial sizes printed beside them. A compounded vial has no such table, no published maximum a pharmacist can point at, and no label to read the caution out of.
What the Label Does Not Say
Honesty sits at the edge of this subject, so here it is. The label does not describe 0.25 mg as producing glycemic control, and no approved Ozempic dose exists above 2 mg weekly for the pen. There is no approved dosing for compounded semaglutide at any strength, and no trial data in the label for doses pushed past the ceiling. Whether an individual responds well at 0.5 mg or needs 2 mg is a clinical judgment about that person’s blood sugar, kidneys, stomach tolerance and other medicines, and it belongs to a prescriber who can see those numbers. Reading a chart is not the same act as being treated.
Frequently asked questions
What is the starting Ozempic dosage?
For the weekly injection, 0.25 mg once weekly for four weeks. For the daily Ozempic tablets, 1.5 mg once daily for the first 30 days. Both are tolerance steps, and the tablet label states its starting dose is not effective for glycemic control.
How long do you stay at 0.25 mg?
Four weeks, according to section 2.2 of the injection label. That four-week block appears again at each later step, which is why the label’s own timeline reaches 2 mg at about week 13 at the quickest.
What is the highest Ozempic dose?
2 mg once weekly for the injection, and the 2 mg step requires at least four weeks at 1 mg first. The daily tablets top out at 9 mg once daily. The two ceilings are not comparable numbers.
What should you do if you miss a weekly Ozempic dose?
The label gives a five-day window. Take the missed dose as soon as possible within five days. Past five days, skip it, take the next dose on the regular day, and resume the weekly pattern. Changing the shot day requires more than 48 hours between two doses.
Is the Ozempic dosage for weight loss different from the diabetes dosage?
The injection is not approved for weight loss, so there is no approved weight-loss dose of Ozempic to compare. Weight-loss treatment with this molecule runs under a different brand and a different label, which is where the higher ceiling lives. Our clinic directory page for treatment options near you is a starting point for finding a prescriber rather than a chart.
Can you switch between Ozempic injections and tablets freely?
The label publishes specific switch paths and describes the tablets as not substitutable on a milligram-to-milligram basis. Rybelsus 7 mg maps to Ozempic tablets 4 mg, and Rybelsus 14 mg maps to Ozempic tablets 9 mg. From the 0.5 mg injection, the tablets can start one week after the last injection. Paths outside those rows are not addressed in the label at all, which is a question for a prescriber, not an internet table.
Does a compounded semaglutide vial follow the same dosage schedule?
It cannot, because the schedule belongs to products the FDA approved. The agency reports hospitalizations tied to dosing errors with compounded injectable semaglutide and reports of doses beyond the approved label. There is no approved maximum for a compounded vial to hold a prescriber to.
Sources: FDA prescribing information for Ozempic injection, sections 1, 2.1, 2.2 and 6.1, FDA labeling for Ozempic tablets and Rybelsus, revised 1 January 2026, FDA concerns with unapproved GLP-1 drugs used for weight loss, FDA statement that the semaglutide injection shortage is resolved and compounding policy narrowed, 21 February 2025.
A pen holding the same molecule draws the missed-dose line somewhere else. The label on the Ozempic box measures the gap in five days, and the ladder stops at 2 mg: semaglutide for weight loss, measured against the numbers in the FDA label.